stella
beta
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Stella
Recruiting
Back to Sickle Cell Disease trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
Boston Children's Hospital, Boston, Massachusetts
View full record on ClinicalTrials.gov